PULMONARY-RENAL SYNDROME: DIFFICULTIES OF DIFFERENTIAL DIAGNOSIS

Cover Page

Cite item

Full Text

Abstract

The study objective is to demonstrate the difficulty of differential diagnosis in pulmonary-renal syndrome using a clinical case as an example.

Materials and methods. Male patient A., 68 years old, retired, was hospitalized at the N.I. Pirogov City Clinical Hospital № 1 in December of 2017 with complaints of inefficient cough, fever of 39 °С, weakness, apnea, weight loss up 10 kg in 3 months. Examination revealed skin and mucosa paleness, calf edema, heart beat of 102 bpm, normal rhythm, arterial pressure 130/80 mm Hg, respiratory rate 22 breaths per min. Auscultation revealed harsh respiration in the lungs, weakened in the lower parts, fine moist rales. Anemia (hemoglobin – 53 g/l, erythrocytes – 1.85 × 1012/l, serum iron – 3.1 µmol/l), elevated urea up to 41.4 mmol/l, creatinine up to 843.1 µmol/l (glomerular filtration rate – 6 ml/min/1.73 m2), leukocytes up to 12.5 × 109/l, С-reactive protein up to 124.96 mg/l were diagnosed. Clinical urine analysis showed proteinuria 0.47 g/l. Computed tomography of the chest revealed pronounced infiltrative changes in tissues of both lungs, more on the right, alveolitis, bronchiolitis in the middle lobe on the right, 5th segment on the left. Lymphadenopathy mediastinal was diagnosed. After examination (multiple bacteriological blood, sputum tests, interferon-gamma release assay, echocardiography, bronchoalveolar lavage, sterna puncture, esophagogastroduodenoscopy, colonoscopy, etc.), oncological pathology, tuberculosis of the lungs, sepsis, infections endocarditis and other infectious pathologies were excluded. Antibacterial courses prescribed earlier were ineffective. Immunological blood test revealed high titers (1:1280) of antineutrophil cytoplasmic antibodies (ANCA) with perinuclear fluorescence type (myeloperoxidase specificity), negative antibodies to glomerular basal membrane which allowed to diagnose ANCA-associated vasculitis.

Results. Considering the data of clinical, lab, and instrumental examination, the patient was diagnosed with microscopic polyangiitis, ANCA-associated, affecting the lungs (disseminated interstitial lung disease with bronchiolitis) and kidneys (rapidly progressive glomerulonephritis), intrathoracic lymphadenopathy, activity grade III (BVAS index – 23 points). Grade II respiratory failure. Chronic kidney disease 5D (glomerular filtration rate – 6 ml/min/1.73 m2). Grade II arterial hypertension, risk 4. Grade II pulmonary hypertension. Chronic heart failure 2А, functional class IV. Mixed anemia (iron-deficient, chronic disease), severe. Disseminated polyposis of the colon (hyperplastic type). At the hospital, antibacterial drugs (cefoperazone sulbactam), antifungal (fluticasone) were administered, anemia was corrected (iron-containing drugs and erythropoietin, hemotransfusion), hemodialysis. Cyclophosphane 400 mg was administered intravenously, a week later – 800 mg. Methylprednisolone (60 mg/day), co-trimoxazole (480 mg 3 times a week) were prescribed. A pronounced improvement was observed due to the therapy: body temperature normalization, decreased apnea, cough, weakness, increased appetite. The patient was discharged with recommendation for continuation of cytostatic therapy per the regimen and prescription for programmed hemodialysis at the place of residence.

Conclusion. This clinical case demonstrates a necessity of considering ANCA-associated vasculitis during differential diagnosis of pulmonary-renal syndrome. Timely diagnosis and active cytostatic therapy play a principal role in treatment and promote deceleration of disease progression and improve prognosis.

About the authors

D. Yu. Andriyashkina

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Author for correspondence.
Email: andryashkina.darya@yandex.ru
ORCID iD: 0000-0001-8266-6022

Acad. A.I. Nesterov Department of Faculty Therapy

1 Ostrovityanova St., Moscow 117997

Russian Federation

N. A. Demidova

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0001-6890-8777

Acad. A.I. Nesterov Department of Faculty Therapy

1 Ostrovityanova St., Moscow 117997

Russian Federation

N. A. Shostak

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-4669-1006

Acad. A.I. Nesterov Department of Faculty Therapy

1 Ostrovityanova St., Moscow 117997

Russian Federation

N. A. Tutaev

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-2011-8300

Acad. A.I. Nesterov Department of Faculty Therapy

1 Ostrovityanova St., Moscow 117997

Russian Federation

A. D. Ershov

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-1505-7723

Acad. A.I. Nesterov Department of Faculty Therapy

1 Ostrovityanova St., Moscow 117997

Russian Federation

D. K. Dudin

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-2668-344X

Acad. A.I. Nesterov Department of Faculty Therapy

1 Ostrovityanova St., Moscow 117997

Russian Federation

References

  1. Federal clinical guidelines for the diagnosis and treatment of systemic vasculitis, 2013. URL access mode: https://diseases.medelement.com/disease/системныеваскули-рекомендациирф/15090. (In Russ.)
  2. Shostak N.A., Klimenko A.A. Systemic vasculitis: new in classification, diagnosis and treatment. Klinitsist = The Clinician 2015;9(2):8–12. (In Russ.)
  3. Jennette J.C., Falk R.J., Hu P, Xiao H. et al. Pathogenesis of antineutrophil cytoplasmic autoantibody – associated small-vessel vasculitis. Annu Rev Pathol 2013;8(1):139–60.
  4. Jennette J.C., Falk R.J., Hu P, Xiao H. et al. Pathogenesis of antineutrophil cytoplasmic autoantibody – associated small-vessel vasculitis. Annu Rev Pathol 2013;8(1):139–60.
  5. Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65(1):1–11.
  6. Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65(1):1–11.
  7. Ntatsaki E., Watts R.A., Scott D.G. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 2010;36(3):447–61.
  8. Ntatsaki E., Watts R.A., Scott D.G. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 2010;36(3):447–61.
  9. Watts R.A., Mooney J., Skinner J. et al. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rheumatology (Oxford) 2012;51(5):926–31.
  10. Watts R.A., Mooney J., Skinner J. et al. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rheumatology (Oxford) 2012;51(5):926–31.
  11. Fujimoto S., Watts R.A., Kobayashi S. et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody vasculitis between Japan and the U.K. Rheumatology (Oxford) 2011;50(10):1916–20.
  12. Fujimoto S., Watts R.A., Kobayashi S. et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody vasculitis between Japan and the U.K. Rheumatology (Oxford) 2011;50(10):1916–20.
  13. Kozlovskaya N.L., Gordovskaya N.B., Korotchaeva Yu.V. PROJECT of National guidelines for the diagnosis and treatment of ANCA-associated glomerulonephritis (kidney damage in ANCA-associated vasculitis), 2014. URL access mode: http://nonr.ru/wp-content/uploads/2013/11/Рекомендации-поАНЦА-ГН-оконч.pdf. (In Russ.)
  14. Kozlovskaya N.L., Gordovskaya N.B., Korotchaeva Yu.V. PROJECT of National guidelines for the diagnosis and treatment of ANCA-associated glomerulonephritis (kidney damage in ANCA-associated vasculitis), 2014. URL access mode: http://nonr.ru/wp-content/uploads/2013/11/Рекомендации-поАНЦА-ГН-оконч.pdf. (In Russ.)
  15. Khan I., Watts R.A. Classification of ANCA-associated vasculitis. Curr Rheumatol Rep 2013;15(12):383. doi: 10.1007/s11926-013-0383-6.
  16. Khan I., Watts R.A. Classification of ANCA-associated vasculitis. Curr Rheumatol Rep 2013;15(12):383. doi: 10.1007/s11926-013-0383-6.
  17. Moiseev S.V., Novikov P.I., Meshkov A.D., Ivanitskiy L.V. ANCA-associated vasculitis: controversial issues of classification, diagnosis and evaluation of activity and current approaches to treatment. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy 2014;23(1):44–50. (In Russ.)
  18. Moiseev S.V., Novikov P.I., Meshkov A.D., Ivanitskiy L.V. ANCA-associated vasculitis: controversial issues of classification, diagnosis and evaluation of activity and current approaches to treatment. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy 2014;23(1):44–50. (In Russ.)
  19. Semenkova E.N. Systemic necrotizing vasculitis. Moscow: Russian Doctor, 2001. 96 p. (In Russ.)
  20. Semenkova E.N. Systemic necrotizing vasculitis. Moscow: Russian Doctor, 2001. 96 p. (In Russ.)
  21. Nasonov E.L., Baranov A.A., Shilkina N.P. Vasculitis and vasculopathy. Yaroslavl: Upper Volga, 1999. 616 p. (In Russ.)
  22. Nasonov E.L., Baranov A.A., Shilkina N.P. Vasculitis and vasculopathy. Yaroslavl: Upper Volga, 1999. 616 p. (In Russ.)
  23. Flossmann O., Berden A., de Groot K. et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70(3):488–94.
  24. Flossmann O., Berden A., de Groot K. et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70(3):488–94.
  25. Jones R.B., Tervaert J.W., Hauser T. et al. European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363(3):211–20.
  26. Jones R.B., Tervaert J.W., Hauser T. et al. European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363(3):211–20.
  27. Stone J.H., Merkel P.A., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363(3):221–32.
  28. Stone J.H., Merkel P.A., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363(3):221–32.
  29. Charles P., Bienvenu B., Bonnotte B. et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013;42(10):1317–30.
  30. Charles P., Bienvenu B., Bonnotte B. et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013;42(10):1317–30.
  31. Guillevin L., Pagnoux C., Seror R. et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 2011;90(1):19–27
  32. Guillevin L., Pagnoux C., Seror R. et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 2011;90(1):19–27

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36931 от  21.07.2009.